Spots Global Cancer Trial Database for toripalimab injection
Every month we try and update this database with for toripalimab injection cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer | NCT05033392 | Stomach Neoplas... | Toripalimab Inj... | 18 Years - 79 Years | Shenzhen People's Hospital | |
| Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma | NCT04605185 | Unresectable He... | Donafenib Tosil... Toripalimab Inj... | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | NCT06095583 | Limited-stage S... | Tifcemalimab in... toripalimab inj... Placebo for Tif... Placebo for tor... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | NCT06208410 | Advanced Solid ... | JS105 Fulvestrant inj... Dalpiciclib Ise... Toripalimab Inj... Paclitaxel for ... Fluzoparib Caps... Pyrotinib Malea... Capecitabine Ta... | 18 Years - 75 Years | Risen (Suzhou) Pharma Tech Co., Ltd. | |
| Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | NCT04613804 | NSCLC Stage IV | Toripalimab Inj... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | NCT06095583 | Limited-stage S... | Tifcemalimab in... toripalimab inj... Placebo for Tif... Placebo for tor... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer | NCT04856631 | Head and Neck S... | Toripalimab Inj... Cetuximab Solut... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) . | NCT04234620 | Melanoma Lung Cance Breast Cancer | Toripalimab inj... | - | Shanghai Junshi Bioscience Co., Ltd. | |
| Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | NCT04613804 | NSCLC Stage IV | Toripalimab Inj... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer | NCT05033392 | Stomach Neoplas... | Toripalimab Inj... | 18 Years - 79 Years | Shenzhen People's Hospital | |
| Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors | NCT05102006 | Advanced Solid ... | LBL-007 Injecti... Toripalimab Inj... | 18 Years - 75 Years | Nanjing Leads Biolabs Co.,Ltd | |
| Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors | NCT05102006 | Advanced Solid ... | LBL-007 Injecti... Toripalimab Inj... | 18 Years - 75 Years | Nanjing Leads Biolabs Co.,Ltd | |
| PD-1 Antibody for Reactive EBV After BMT | NCT04690036 | PD-1 EBV Infection Transplant | toripalimab inj... | 18 Years - | Beijing Friendship Hospital | |
| PD-1 Antibody for Reactive EBV After BMT | NCT04690036 | PD-1 EBV Infection Transplant | toripalimab inj... | 18 Years - | Beijing Friendship Hospital | |
| Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma | NCT05451407 | Melanoma | TQB2618 injecti... Toripalimab inj... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT06378177 | Head and Neck S... | LVGN6051 Monocl... toripalimab Inj... Paclitaxel inje... | 18 Years - | Lyvgen Biopharma Holdings Limited | |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | NCT06208410 | Advanced Solid ... | JS105 Fulvestrant inj... Dalpiciclib Ise... Toripalimab Inj... Paclitaxel for ... Fluzoparib Caps... Pyrotinib Malea... Capecitabine Ta... | 18 Years - 75 Years | Risen (Suzhou) Pharma Tech Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
